Based on datasets from Oncomine and Gene Expression Omnibus, RFWD2 is found to be overexpressed in various human cancers, including leukemia, lung cancer, breast cancer, renal cell carcinoma, colorectal cancer, ovarian cancer, and hepatocellular carcinoma (12). This evidence concerns the gene COP1 and lung carcinoma.